Pacific Biosciences of California, Inc.

Good day, and welcome to PACBio's second quarter of 2026 earnings call. All participants will be in a listen only mode for the duration of the call. And should you need any assistance today, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. If you'd like to ask a question, you may press star one on your telephone keypad to join the queue. and to withdraw a question for any reason, please press star then two. Also, please be aware that today's call is being recorded. I'd now like to turn the call over to Kayleen Parrish from Gilmartin Group. Please go ahead.

Good afternoon and welcome to PACBio's second quarter 2026 earnings conference call. With me today are Mark Van Oene, President and Chief Executive Officer, Jim Gibson, Chief Financial Officer and Christian Henry, PACBio board member and advisor. Earlier today, we issued a press release outlining the financial results we'll be discussing on today's call, a copy of which is available on the Investors section of our website at www.pacb.com or as furnished on Form 8K, available on the Securities and Exchange Commission website at www.sec.gov. A copy of our earnings presentation is also available on the Investors section of our website. On today's call, we will make forward-looking statements, including, among others, statements providing predictions, estimates, expectations, and guidance. You should not place undue reliance on forward-looking statements because they are subject to assumptions, risks, and uncertainties that could cause our actual results to differ materially from those projected or discussed. Please review our SEC filings, including our most recent Form 10-Q and 10-K and our press releases, to better understand the risks and uncertainties that could cause results to differ. We disclaim any obligation to update or revise these forward-looking statements, except as required by law. We also present certain financial information on a non-GAAP basis, which is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of the company's operating results as reported under U.S. GAAP. Reconciliations between historical U.S. GAAP and non-GAAP results are presented in our earnings release, which is available on the Investors section of our website. For future periods, we're unable to reconcile non-GAAP gross margin and non-GAAP operating expenses without unreasonable effort due to the uncertainty regarding, among other matters, certain acquisition-related items that may arise during the year. A recording of today's call will be available shortly after the live call in the Investors section of our website. Those electing to use the replay are cautioned that forward-looking statements may differ or change materially after the completion of the live call. I will now turn the call over to Christian.

Thank you and good afternoon everyone. Earlier today we announced that I am stepping down as President and Chief Executive Officer of PacBio and that Mark Van Oene will lead the company as President and Chief Executive Officer effective immediately. I will remain on the Board of Directors and become an advisor to Mark as he drives PacBio's strategy forward. Mark joined PacBio shortly after I did and in that time, he has led the R&D, operations and commercial organizations. His deep understanding of the genomics and clinical markets will be invaluable to the company as we move deeper into supporting clinical sequencing around the globe. Additionally, his ability to successfully lead strong teams will ensure that PacBio executes well into its future. I am proud of what we have accomplished over the nearly six years that I have had the privilege of leading PacBio. We have developed and launched groundbreaking new long read sequencers that have dramatically improved the scale and economics of long read sequencing. These platforms are enabling researchers and clinicians to dramatically improve their ability to understand the impact of genetic variation on disease, moving us closer to achieving our mission of Enabling the Promise of Genomics to Improve Human Health. Finally, I want to thank our employees, customers, and collaborators for their support. I look forward to advising Mark as he leads the company into its next phase of growth and continuing to serve on the board of directors. With that, I'll now turn the call over to Mark. Mark?